Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fluorouracil (5-FU) is not a therapeutic target such as a receptor, enzyme, or transporter. It is itself a drug—an antimetabolite chemotherapeutic agent. The query asks about "target molecule/receptor," but fluorouracil is not a target; it acts on cellular targets such as thymidylate synthase and DNA/RNA synthesis pathways. Therefore, this entry does not fit the intended use of "target" in drug discovery or pharmacology.
Fluorouracil (5-FU) is a pyrimidine analog antimetabolite. It is converted intracellularly to several active metabolites, including fluorodeoxyuridine monophosphate (FdUMP), which inhibits thymidylate synthase (TS), leading to depletion of thymidine nucleotides and disruption of DNA synthesis. Fluorouridine triphosphate (FUTP) is incorporated into RNA, interfering with RNA processing and function. Fluorodeoxyuridine triphosphate (F-dUTP) can be incorporated into DNA, leading to DNA damage and fragmentation. These actions collectively disrupt nucleic acid synthesis and function, causing cell cycle arrest and apoptosis, particularly in rapidly proliferating cells.
10 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fluorouracil (5-Fluorouracil) (5-FU).